Vigilant Biosciences Revenue and Competitors

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral and oropharyngeal cancer. Vigilant's BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarker CD44 and total protein – markers clinically validated to be associated with oral cancer when measured in an oral rinse – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple, oral saline rinse collection that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Kris Foss, Vice President, Regulatory, Quality & Clinical